🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 103 of 116

  1. Pevonedistat

    Takeda

    Advanced Solid Neoplasm

    phase 1 small molecule completed

    2 trials

  2. Pevonedistat

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  3. Pevonedistat 25 mg/m^2

    Takeda

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  4. Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

    Topiloric/Uriadec

    Prostate cancer

    phase 1 other active

    1 trial

  5. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  6. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  7. Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  8. Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  9. Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers

    Immunocore Ireland Limited

    Advanced PRAME Positive Cancers

    phase 1 other active

    1 trial

  10. Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer

    Janssen-Cilag International N.V.

    Metastatic colorectal cancer and Gastric cancer

    phase 1 other active

    1 trial

  11. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    Olema Pharmaceuticals

    Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  12. Phase 1 Study of PYX-106 in Solid Tumors

    Pyxis Oncology

    Solid Tumors

    phase 1 other active

    1 trial

  13. Phase 1 Study of PYX-201 in Solid Tumors

    Pyxis Oncology

    Advanced solid tumors

    phase 1 other active

    1 trial

  14. Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 other active

    1 trial

  15. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  16. Phase 1 trial of valemetostat and darolutamide in mCRPC

    Daiichi Sankyo

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  17. Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  18. Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

    Janssen-Cilag International N.V.

    Localized Bladder Cancer

    phase 1 other active

    1 trial

  19. Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  20. Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

  21. Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 other active

    1 trial

  22. Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  23. Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

    The George Institute

    Non-small cell lung cancer (NSCLC)

    phase 1 other active

    1 trial

  24. Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 1 other active

    1 trial

  25. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  26. Phase I study of 225Ac-PSMA I&T in prostate cancer

    Disc Medicine

    metastatic prostate cancer

    phase 1 other active

    1 trial

  27. Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  28. Phase I study of MGY825 in patients with lung cancer

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients

    phase 1 other active

    1 trial

  29. Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced solid tumors

    phase 1 other active

    1 trial

  30. Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer

    Disc Medicine

    Cervical Cancer

    phase 1 other active

    1 trial

  31. Pitavastatin

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  32. Placebo for antibiotic

    Seres Therapeutics

    Metastatic Melanoma

    phase 1 small molecule completed

    1 trial

  33. Plerixafor

    United Therapeutics Europe Ltd

    Pancreatic Adenocarcinoma Metastatic

    phase 1 small molecule completed

    1 trial

  34. Pluvicto 1 000 MBq/mL solution for injection/infusion, Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    PSMA-positive non-curative metastatic castration-resistant prostate cancer

    phase 1 small molecule active

    1 trial

  35. Ponatinib

    Takeda

    Chronic Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  36. Prizloncabtagene Autoleucel

    The First People's Hospital of Lianyungang

    Non-Hodgkin's B-cell Lymphoma

    phase 1 mab active

    1 trial

  37. Prospective feasibility pilot study evaluating the value of [68Ga]Ga-PENTIXAFOR PET-CT in patients with locally advanced or metastatic Small Cell Lung Cancer (SCLC) at diagnosis and disease progression (PASSIFLORE)

    CERO THERAPEUTICS HOLDINGS, INC.

    cell lung carcinoma

    phase 1 other active

    1 trial

  38. Proxalutamide

    The First People's Hospital of Lianyungang

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  39. Pyrotinib low dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  40. QEQ278

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 mab terminated

    1 trial

  41. RAD 001 in combination with Caelyx

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  42. RBL001/RBL002

    Atrium Therapeutics

    Melanoma

    phase 1 mab completed

    1 trial

  43. REGN1400

    Regeneron UK Limited

    Cancer

    phase 1 small molecule completed

    1 trial

  44. REGN2810

    Regeneron UK Limited

    Recurrent Squamous Cell Carcinoma of Head

    phase 1 small molecule completed

    1 trial

  45. REGN2810

    Regeneron UK Limited

    Melanoma

    phase 1 small molecule completed

    1 trial

  46. REGN4659

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule terminated

    1 trial

  47. REGN5678

    Regeneron UK Limited

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  48. REGN6569

    Regeneron UK Limited

    Squamous Cell Carcinoma of Head and Neck

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.